Nanomedicine-Based Drug Delivery for Infectious Diseases: Advances, Challenges, And Future Perspectives

Abstract

Nanomedicine has emerged as a transformative approach in the treatment of infectious diseases by enabling targeted drug delivery, improved pharmacokinetics, and enhanced therapeutic efficacy. Conventional antimicrobial therapies face limitations such as poor bioavailability, systemic toxicity, and increasing antimicrobial resistance (AMR). Nanoparticle-based drug delivery systems—including liposomes, polymeric nanoparticles, dendrimers, and metallic nanostructures—offer innovative solutions by facilitating site-specific delivery, controlled release, and biofilm penetration. Recent advances highlight the integration of nanotechnology with antimicrobial agents, vaccines, and gene therapies to combat bacterial, viral, and fungal infections. Despite promising preclinical outcomes, challenges such as toxicity, scalability, regulatory hurdles, and clinical translation remain significant barriers. This review provides a comprehensive overview of nanomedicine strategies in infectious disease treatment, discusses current advancements, and outlines future directions toward clinical application.

Keywords

Introduction

Infectious diseases remain one of the most pressing challenges to global health, accounting for a substantial proportion of morbidity and mortality worldwide. According to recent global health estimates, infectious diseases are responsible for millions of deaths annually, with lower- and middle-income countries bearing a disproportionate burden due to limited healthcare access and infrastructure. The situation has been further exacerbated by the rapid emergence and spread of antimicrobial resistance (AMR), which has become a major threat to public health, food security, and economic stability. Recent projections suggest that, if left unaddressed, AMR could lead to up to 10 million deaths per year by 2050, surpassing mortality rates associated with cancer and other chronic diseases (O’Neill, 2016; Murray et al., 2022).

Despite the availability of a wide range of antimicrobial agents, conventional therapeutic approaches often fail to achieve optimal clinical outcomes. This is primarily due to several inherent limitations associated with traditional drug delivery systems, including poor solubility, low bioavailability, rapid systemic clearance, and nonspecific distribution of drugs. These challenges not only reduce therapeutic efficacy but also increase the risk of systemic toxicity and adverse side effects. Furthermore, many pathogens have developed sophisticated defense mechanisms, such as biofilm formation, intracellular survival, and efflux pump activity, which significantly limit the effectiveness of conventional antibiotics (Zou et al., 2023; Ahmed et al., 2025).

Biofilms, in particular, represent a critical barrier in the treatment of chronic and device-associated infections. It is estimated that nearly 65–80% of all microbial infections involve biofilm formation, where microorganisms are embedded within a self-produced extracellular polymeric matrix. This structure protects pathogens from host immune responses and antimicrobial agents, often requiring antibiotic concentrations up to 1,000 times higher than those needed for planktonic cells (Farah & Kadhim-Abosaoda, 2026). Consequently, there is an urgent need for innovative therapeutic strategies that can overcome these biological barriers and enhance drug delivery to infection sites.

In recent years, nanomedicine has emerged as a promising and transformative approach in the field of infectious disease treatment. Nanomedicine involves the application of nanoscale materials, typically ranging from 1 to 100 nm, for diagnostic and therapeutic purposes. Nanoparticle-based drug delivery systems offer several advantages over conventional formulations due to their unique physicochemical properties, including high surface area-to-volume ratio, tunable surface chemistry, and the ability to encapsulate both hydrophilic and hydrophobic therapeutic agents. These characteristics enable improved drug stability, enhanced permeability across biological barriers, and controlled or stimuli-responsive drug release (Bharti & Kumar, 2025; Mouzakis et al., 2025).

One of the key advantages of nanomedicine lies in its ability to facilitate targeted drug delivery. By functionalizing nanoparticle surfaces with ligands such as antibodies, peptides, or small molecules, it is possible to achieve selective binding to infected tissues or microbial cells. This targeted approach enhances drug accumulation at the site of infection while minimizing systemic exposure and associated toxicity. Additionally, nanoparticles can be engineered to respond to specific environmental triggers, such as pH changes, enzymatic activity, or temperature variations, allowing for site-specific drug release in infected tissues (Zou et al., 2023; Oso et al., 2025).

Nanomedicine also offers significant potential in overcoming antimicrobial resistance. Unlike conventional antibiotics, nanoparticle-based systems can bypass common resistance mechanisms, including efflux pumps and enzymatic degradation. Metallic nanoparticles, such as silver and zinc oxide, exhibit intrinsic antimicrobial activity through mechanisms including reactive oxygen species (ROS) generation, membrane disruption, and interference with microbial DNA. Furthermore, nanocarriers can be used to deliver combination therapies, enhancing synergistic effects and reducing the likelihood of resistance development (Elbehiry & Abalkhail, 2025).

Another important application of nanomedicine is in improving intracellular drug delivery. Many pathogens, such as Mycobacterium tuberculosis and certain viruses, reside within host cells, making them difficult to target using conventional therapies. Nanoparticles can facilitate cellular uptake through endocytosis and deliver drugs directly to intracellular compartments, thereby improving therapeutic efficacy. This approach has shown promising results in the treatment of tuberculosis, viral infections, and other intracellular pathogens (Ahmed et al., 2025).

Recent advancements have also demonstrated the role of nanomedicine in vaccine development and immunotherapy. Nanoparticle-based platforms have been successfully utilized in the development of mRNA vaccines and adjuvant systems, as evidenced during the COVID-19 pandemic. These systems enhance antigen stability, improve immune response, and enable targeted delivery to immune cells, highlighting the versatility of nanotechnology in infectious disease management.

2. TYPES OF NANOCARRIERS IN INFECTIOUS DISEASE DRUG DELIVERY

2.1 Lipid-Based Nanocarriers

Lipid-based nanocarriers, including liposomes and solid lipid nanoparticles (SLNs), are among the most extensively studied systems for antimicrobial drug delivery. Their high biocompatibility and ability to encapsulate both hydrophilic and hydrophobic therapeutic agents make them particularly attractive for clinical applications. These carriers enhance drug stability, prolong circulation time, and reduce systemic toxicity by improving drug localization at the site of infection. Notably, liposomal formulations of antibiotics have demonstrated improved intracellular delivery, especially against pathogens such as Mycobacterium tuberculosis, which reside within host cells (Zou et al., 2023).

2.2 Polymeric Nanoparticles

Polymeric nanoparticles, particularly those based on biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), offer significant advantages in controlled and sustained drug release. Their structural versatility allows for surface modification with targeting ligands, enabling selective delivery to infected tissues or cells. In addition, these systems provide protection to encapsulated drugs from premature degradation, thereby enhancing therapeutic efficiency. Recent studies have highlighted their potential in delivering antimicrobial peptides and improving their stability against enzymatic breakdown (Ahmed et al., 2025).

2.3 Metallic Nanoparticles

Metallic nanoparticles, including silver, gold, and zinc oxide nanoparticles, possess inherent antimicrobial properties that distinguish them from conventional drug carriers. Their mechanisms of action involve the generation of reactive oxygen species (ROS), disruption of microbial membranes, and interference with cellular components such as DNA and proteins. Among these, silver nanoparticles have received considerable attention due to their strong and broad-spectrum antimicrobial activity, particularly against biofilm-forming microorganisms that are typically resistant to standard antibiotics (Singh, 2025).

2.4 Dendrimers and Carbon-Based Nanomaterials

Dendrimers are highly branched, nanoscale polymers with well-defined structures that allow for multivalent interactions with biological targets. Their architecture enables efficient drug loading and precise surface functionalization, making them suitable for targeted drug delivery applications. In parallel, carbon-based nanomaterials such as graphene and carbon nanotubes have emerged as promising platforms due to their unique physicochemical and antimicrobial properties. These materials have shown potential in a range of applications, including antiviral therapy and gene delivery, owing to their ability to interact with biological membranes and facilitate cellular uptake (Elbehiry & Abalkhail, 2025).

3. MECHANISMS OF NANOMEDICINE IN COMBATING INFECTIOUS DISEASES

Nanomedicine offers multiple innovative mechanisms to enhance the effectiveness of antimicrobial therapies. By leveraging the unique physicochemical properties of nanoparticles, these systems can overcome biological barriers and improve drug performance at infection sites.

3.1 Targeted Drug Delivery

One of the most significant advantages of nanomedicine is its ability to deliver drugs selectively to infected tissues or microbial cells. Nanoparticles can be functionalized with targeting ligands such as antibodies, peptides, or small molecules that recognize specific receptors expressed on pathogens or infected host cells. This targeted approach increases drug accumulation at the site of infection while minimizing off-target effects and systemic toxicity, ultimately improving therapeutic outcomes (Bharti & Kumar, 2025; Zou et al., 2023).

3.2 Controlled and Stimuli-Responsive Drug Release

Nanocarrier systems can be engineered to release their therapeutic payload in a controlled manner over time or in response to specific environmental triggers. Factors such as pH changes, enzymatic activity, and temperature variations at infection sites can be utilized to activate drug release. This controlled and stimuli-responsive behavior ensures that drugs are released precisely where and when they are needed, enhancing efficacy while reducing unnecessary exposure to healthy tissues (Ishaque, 2025).

3.3 Biofilm Penetration and Disruption

Biofilms present a major challenge in the treatment of persistent infections due to their dense extracellular matrix, which limits antibiotic penetration. Nanoparticles, owing to their small size and modifiable surface properties, can effectively penetrate biofilm structures and deliver antimicrobial agents directly to embedded pathogens. In addition, certain nanomaterials can disrupt the biofilm matrix itself, further enhancing drug accessibility and therapeutic effectiveness (Farah & Kadhim-Abosaoda, 2026).

3.4 Overcoming Antimicrobial Resistance

Nanomedicine provides several strategies to counteract antimicrobial resistance (AMR). Nanoparticles can bypass traditional resistance mechanisms such as efflux pumps and enzymatic degradation. Moreover, some nanomaterials exhibit intrinsic antimicrobial activity through mechanisms like reactive oxygen species (ROS) generation, membrane damage, and interference with microbial genetic material. The use of nanocarriers for combination therapy also enables synergistic effects, reducing the likelihood of resistance development (Ahmed et al., 2025; Oso et al., 2025).

4. APPLICATIONS OF NANOMEDICINE IN INFECTIOUS DISEASES

Nanomedicine has demonstrated significant potential across a broad spectrum of infectious diseases, offering innovative solutions to overcome the limitations of conventional therapeutic approaches. Its applications extend to bacterial, viral, fungal, and pulmonary infections, where nanoparticle-based systems enhance drug delivery, improve therapeutic efficacy, and reduce adverse effects.

4.1 Bacterial Infections

Nanoparticle-based drug delivery systems have shown considerable promise in the treatment of bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens. By improving drug stability and facilitating targeted delivery, nanocarriers enhance the effectiveness of existing antibiotics while minimizing systemic toxicity. These systems are especially valuable in treating infections such as tuberculosis, sepsis, and chronic wound infections, where conventional therapies often fail. Additionally, nanoparticles can penetrate bacterial biofilms and deliver high local concentrations of antimicrobial agents, thereby improving treatment outcomes (Ahmed et al., 2025; Zou et al., 2023).

4.2 Viral Infections

In the context of viral diseases, nanomedicine has played a crucial role in both therapeutic and preventive strategies. Nanocarriers enable efficient delivery of antiviral drugs by enhancing their stability and bioavailability. Moreover, nanoparticle-based platforms have been widely utilized in vaccine development, including lipid nanoparticle systems used for mRNA vaccines. These technologies improve antigen delivery, enhance immune responses, and allow for targeted interaction with immune cells, as demonstrated during the COVID-19 pandemic (Mouzakis et al., 2025; Bharti & Kumar, 2025).

4.3 Fungal Infections

Fungal infections, particularly systemic mycoses, are often associated with high toxicity and poor solubility of antifungal drugs. Nanomedicine offers a promising approach to address these challenges by improving drug solubility, reducing toxicity, and enabling targeted delivery. For example, nanoformulations of antifungal agents such as amphotericin B have been shown to significantly reduce nephrotoxicity while maintaining therapeutic efficacy. These advancements highlight the potential of nanotechnology in improving the safety and effectiveness of antifungal therapies (Elbehiry & Abalkhail, 2025).

4.4 Pulmonary Infections

Nanoparticle-based delivery systems have also shown great potential in the treatment of pulmonary infections, including pneumonia, tuberculosis, and viral respiratory diseases. Inhalable nanocarriers allow for direct delivery of drugs to the lungs, thereby increasing local drug concentration while reducing systemic exposure. This targeted approach enhances therapeutic efficiency and minimizes side effects. Recent studies have demonstrated the effectiveness of inhalable nanoparticles in improving drug deposition and retention within lung tissues, making them a promising strategy for respiratory infections (Gao et al., 2025; Sheng et al., 2022).

5. CHALLENGES AND LIMITATIONS OF NANOMEDICINE IN INFECTIOUS DISEASE TREATMENT

Despite the significant progress and promising outcomes associated with nanomedicine-based drug delivery systems, several challenges continue to limit their widespread clinical application. Addressing these issues is essential for the successful translation of nanotechnology from laboratory research to routine clinical practice.

5.1 Toxicity and Biocompatibility Concerns

One of the primary concerns surrounding nanomedicine is the potential toxicity of nanoparticles. Due to their small size and high reactivity, nanoparticles may interact unpredictably with biological systems, leading to oxidative stress, inflammation, or unintended accumulation in vital organs such as the liver, kidneys, and lungs. Additionally, long-term safety data remain limited, making it difficult to fully assess their biocompatibility and potential side effects in humans (Mouzakis et al., 2025; Elbehiry & Abalkhail, 2025).

5.2 Challenges in Large-Scale Manufacturing

The production of nanoparticle-based drug delivery systems on an industrial scale presents significant technical and economic challenges. Achieving consistent particle size, stability, drug loading efficiency, and reproducibility across batches is complex and requires advanced manufacturing techniques. These challenges increase production costs and can hinder commercialization and widespread adoption (Bharti & Kumar, 2025).

5.3 Regulatory and Standardization Issues

The regulatory approval of nanomedicine products remains a complex and evolving process. Currently, there is a lack of universally accepted guidelines for evaluating the safety, efficacy, and quality of nanoparticle-based therapeutics. Regulatory agencies often require extensive characterization and toxicity studies, which can delay product approval. The absence of standardized testing protocols further complicates the comparison and validation of different nanomedicine formulations (Zou et al., 2023; Oso et al., 2025).

5.4 Stability and Storage Limitations

Nanoparticles can be prone to physical and chemical instability during storage, including aggregation, degradation, or premature drug release. These stability issues can affect their therapeutic performance and shelf life. Ensuring long-term stability while maintaining efficacy remains a key challenge in the development of nanocarrier systems (Ahmed et al., 2025).

5.5 Limited Clinical Translation

Although numerous nanomedicine-based systems have demonstrated encouraging results in preclinical studies, only a limited number have successfully progressed to clinical trials or received regulatory approval. This gap between laboratory research and clinical implementation is often attributed to safety concerns, high development costs, and insufficient large-scale clinical data. As a result, the clinical impact of nanomedicine in infectious disease treatment remains relatively modest compared to its theoretical potential (Farah & Kadhim-Abosaoda, 2026).

6. Future Perspectives

Nanomedicine continues to evolve as a promising frontier in the management of infectious diseases, with ongoing research focused on overcoming current limitations and enhancing clinical applicability. Future developments are expected to center on the design of more sophisticated, safe, and efficient nanocarrier systems that can address the growing challenges of antimicrobial resistance and complex infections.

One of the most promising directions is the development of smart and stimuli-responsive nanoparticles capable of precise, on-demand drug release. These systems can be engineered to respond to specific biological signals, such as pH changes, enzymatic activity, or inflammatory markers at infection sites, thereby improving therapeutic specificity and minimizing off-target effects (Zou et al., 2023; Bharti & Kumar, 2025). Additionally, advances in surface functionalization techniques are enabling the creation of highly targeted nanocarriers that can selectively interact with pathogens or infected cells.

The integration of nanomedicine with advanced technologies, including artificial intelligence (AI) and machine learning, is another emerging trend. AI-driven approaches can facilitate the optimization of nanoparticle design, predict biological interactions, and accelerate drug development processes. This convergence of nanotechnology and computational tools has the potential to significantly improve the efficiency and precision of antimicrobial therapies (Oso et al., 2025).

Furthermore, the incorporation of gene-editing technologies, such as CRISPR-Cas systems, into nanoparticle platforms offers new possibilities for directly targeting and modifying microbial genomes. This strategy could provide highly specific treatments for resistant infections and viral diseases, representing a major advancement beyond traditional antimicrobial approaches (Ahmed et al., 2025).

Sustainability and safety are also becoming key priorities in nanomedicine research. The development of biodegradable and green-synthesized nanoparticles aims to reduce environmental impact and improve biocompatibility. Such approaches not only enhance patient safety but also address concerns related to long-term toxicity and nanoparticle accumulation in biological systems (Mouzakis et al., 2025).

In addition, the concept of personalized nanomedicine is gaining increasing attention. By tailoring nanoparticle-based therapies to individual patient characteristics, including genetic profile and disease condition, it may be possible to achieve more effective and precise treatments. This personalized approach is particularly relevant in the context of infectious diseases, where variability in pathogen behavior and host response can significantly influence treatment outcomes.

Despite these advancements, the successful clinical translation of nanomedicine will depend on addressing existing challenges related to regulatory approval, large-scale manufacturing, and long-term safety evaluation. Increased collaboration between researchers, clinicians, industry stakeholders, and regulatory agencies will be essential to establish standardized guidelines and accelerate the development of clinically viable nanotherapeutics (Farah & Kadhim-Abosaoda, 2026).

In summary, the future of nanomedicine in infectious disease treatment is highly promising, with the potential to revolutionize current therapeutic strategies. Continued interdisciplinary research and technological innovation will play a critical role in transforming nanomedicine from an emerging concept into a mainstream clinical solution.

CONCLUSION

Nanomedicine has emerged as a powerful and innovative approach for improving the treatment of infectious diseases, addressing many of the limitations associated with conventional drug delivery systems. By enabling targeted delivery, controlled drug release, and enhanced penetration of biological barriers, nanoparticle-based systems significantly improve therapeutic efficacy while reducing systemic toxicity. These advantages are particularly relevant in the context of antimicrobial resistance (AMR), where traditional therapies are increasingly becoming ineffective.

The diverse range of nanocarriers—including lipid-based systems, polymeric nanoparticles, metallic nanoparticles, and dendrimer-based platforms—demonstrates the versatility of nanotechnology in tackling bacterial, viral, fungal, and pulmonary infections. In addition, the ability of nanoparticles to disrupt biofilms, enhance intracellular drug delivery, and provide intrinsic antimicrobial activity highlights their potential as next-generation therapeutic tools.

Despite these promising developments, several challenges remain, including concerns related to toxicity, large-scale production, regulatory approval, and long-term safety. Bridging the gap between laboratory research and clinical application will require coordinated efforts among researchers, clinicians, and regulatory bodies, along with the establishment of standardized evaluation frameworks.

Looking ahead, advances in smart nanocarrier design, integration with emerging technologies such as artificial intelligence, and the development of sustainable and personalized nanomedicine approaches are expected to further enhance the clinical potential of these systems. Continued interdisciplinary research and well-designed clinical studies will be essential to translate these innovations into safe and effective therapies.

In conclusion, nanomedicine holds significant promise in transforming the landscape of infectious disease management. With continued progress and careful consideration of existing challenges, it has the potential to become a cornerstone of future therapeutic strategies in the fight against global infectious diseases.

REFERENCES

1. Ahmed, N., Abusalah, M. A., Alsharif, K. F., Albrakati, A., Alhazmi, H. A., & Alzahrani, K. J. (2025). Nanomedicine in the fight against multidrug-resistant infections: Emerging strategies and therapeutic applications. International Journal of Nanomedicine, 20, 1123–1145. https://www.tandfonline.com/doi/10.2147/IJN.S547259
2. Bharti, S., & Kumar, A. (2025). Nanotechnology in targeted delivery of antimicrobials and overcoming resistance. BioNanoScience, 15(2), 345–362. https://link.springer.com/article/10.1007/s12668-024-01654-z
3. Elbehiry, A., & Abalkhail, A. (2025). Antimicrobial nanoparticles against superbugs: Mechanisms and applications. Pharmaceuticals, 18(3), 455. https://pmc.ncbi.nlm.nih.gov/articles/PMC12389178/
4. Farah, H., & Kadhim-Abosaoda, M. (2026). Nanomedicine strategies against biofilm-associated infections: Advances, challenges, and translational barriers. MicrobiologyOpen, e70210. https://onlinelibrary.wiley.com/doi/10.1002/mbo3.70210
5. Gao, Y., Wang, W., Yue, X., Zhang, L., & Chen, J. (2025). Inhalable nanoparticle-based drug delivery systems for pulmonary infections. Drug Delivery, 32(1), 1–15. https://www.tandfonline.com/doi/10.1080/10717544.2025.2544683
6. Mouzakis, A., Panagopoulos, P., & Papazoglou, D. (2025). A comprehensive review of nanoparticles in combating antimicrobial resistance. Pathogens, 14(11), 1090. https://www.mdpi.com/2076-0817/14/11/1090
7. Murray, C. J. L., Ikuta, K. S., Sharara, F., et al. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
8. O’Neill, J. (2016). Tackling drug-resistant infections globally: Final report and recommendations. Review on Antimicrobial Resistance. https://amr-review.org
9. Oso, T. A., Okesanya, O. J., & Adebayo, U. O. (2025). Harnessing nanotechnology to combat antimicrobial-resistant pathogens. Beni-Suef University Journal of Basic and Applied Sciences, 14, 45. https://link.springer.com/article/10.1186/s43088-025-00707-w
10. Sheng, G., Tian, N., Duan, H., Sun, Z., & Chu, H. (2022). Advances in therapeutic nanodrug delivery systems for infectious lung diseases. Acta Materia Medica, 1(2), 145–162. https://www.scienceopen.com/doi/10.15212/AMM-2022-0019
11. Singh, R. (2025). Revolutionizing antimicrobial therapies through biofilm-targeted nanomedicine. Current Pharmaceutical Research, 12(1), 55–70. https://cpr.org.in/index.php/files/article/view/123
12. Zou, W., McAdorey, A., Yan, H., & Chen, W. (2023). Nanomedicine to overcome antimicrobial resistance: Challenges and prospects. Nanomedicine, 18(5), 345–360. https://www.tandfonline.com/doi/10.2217/nnm-2023-0022
13. Alidriss, O. M., Alharbi, S. A., & Alshammari, A. (2025). Targeted drug delivery strategies in overcoming antimicrobial resistance. Pharmaceutics, 17(11), 1426. https://www.mdpi.com/1999-4923/17/11/1426